MedTrace Logo

Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus

NCT00371501 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2010-09-16

No results posted yet for this study

Summary

The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).

Conditions

Interventions

DRUG

Rosuvastatin

10mg/day

DRUG

placebo

one tablet/day

DRUG

aspirin

80mg/day

DRUG

placebo

placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • CC Mok, MD, FRCP · Department of Medicine, Tuen Mun Hospital, Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371501 on ClinicalTrials.gov